Disease · MONDO_0009290
Comparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 20
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cipaglucosidase Alfa/Miglustat vs Alglucosidase Alfa/Placebo: deaths from any cause | 0 of 85 | 0 of 38 | 123 | NCT03729362 | Trial comparisons |
| Cipaglucosidase Alfa/Miglustat vs Alglucosidase Alfa/Placebo: serious adverse events | 8 of 85 | 1 of 38 | 123 | NCT03729362 | Trial comparisons |
| Cipaglucosidase Alfa/Miglustat vs Alglucosidase Alfa/Placebo: Number of Participants Improving on Both 6MWD and % Predicted FVC at Week 52 | 14 of 85 | 0 of 37 | 122 | NCT03729362 | Trial comparisons |
| Treatment Continued Group vs Treatment Switched Group: deaths from any cause | 1 of 81 | 0 of 37 | 118 | NCT04138277 | Trial comparisons |
| Treatment Continued Group vs Treatment Switched Group: serious adverse events | 17 of 81 | 10 of 37 | 118 | NCT04138277 | Trial comparisons |
| Alglucosidase Alfa: <18 Years vs Alglucosidase Alfa: >=18 Years: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT01410890 | Trial comparisons |
| Alglucosidase Alfa: <18 Years vs Alglucosidase Alfa: >=18 Years: serious adverse events | 1 of 10 | 0 of 10 | 20 | NCT01410890 | Trial comparisons |
| Albuterol vs Placebo Comparator: Number of Participants With Adverse Events. | 5 of 8 | 5 of 5 | 13 | NCT01885936 | Trial comparisons |
| Albuterol vs Placebo Comparator: deaths from any cause | 0 of 8 | 0 of 5 | 13 | NCT01885936 | Trial comparisons |
| Albuterol vs Placebo Comparator: serious adverse events | 0 of 8 | 0 of 5 | 13 | NCT01885936 | Trial comparisons |
| Clenbuterol vs Placebo Comparator: deaths from any cause | 0 of 8 | 0 of 5 | 13 | NCT01942590 | Trial comparisons |
| Clenbuterol vs Placebo Comparator: Number of Participants With a Change in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Bilirubin Representing Liver Toxicity | 0 of 8 | 0 of 5 | 13 | NCT01942590 | Trial comparisons |
| Clenbuterol vs Placebo Comparator: Number of Participants With a Change in Creatine Kinase (CK) Reflecting Worsening of Muscle Involvement | 1 of 8 | 0 of 5 | 13 | NCT01942590 | Trial comparisons |
| Clenbuterol vs Placebo Comparator: serious adverse events | 1 of 8 | 0 of 5 | 13 | NCT01942590 | Trial comparisons |
| rAAV1-CMV-GAA Administration-cohort 1 vs rAAV1-CMV-GAA Administration-cohort 2: deaths from any cause | 1 of 3 | 0 of 9 | 12 | NCT00976352 | Trial comparisons |
| rAAV1-CMV-GAA Administration-cohort 1 vs rAAV1-CMV-GAA Administration-cohort 2: serious adverse events | 1 of 3 | 3 of 9 | 12 | NCT00976352 | Trial comparisons |
| Regimen A: Alglucosidase Alfa and Cyclophosphamide vs Regimen B: Alglucosidase Alfa, Rituximab and Methotrexate: deaths from any cause | 0 of 1 | 1 of 3 | 4 | NCT00701701 | Trial comparisons |
| Regimen A: Alglucosidase Alfa and Cyclophosphamide vs Regimen B: Alglucosidase Alfa, Rituximab and Methotrexate: serious adverse events | 1 of 1 | 3 of 3 | 4 | NCT00701701 | Trial comparisons |
| Alglucosidase Alfa 4000 L Material (Non-US Participants) vs Alglucosidase Alfa 160 L Material (US Participants): Number of Participants With Invasive Ventilator-Free Survival | 1 of 1 | 2 of 3 | 4 | NCT01597596 | Trial comparisons |
| Alglucosidase Alfa 4000 L Material (Non-US Participants) vs Alglucosidase Alfa 160 L Material (US Participants): serious adverse events | 0 of 1 | 3 of 3 | 4 | NCT01597596 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009290/comparisons